Abstract Number: 712 • 2014 ACR/ARHP Annual Meeting
Mapping the Disease-Specific Lupusqol to the SF-6D
Background/Purpose: The LupusQoL is a measure of health-related quality of life (HRQoL) developed specifically to assess the impact of systemic lupus erythematosus (SLE) and its…Abstract Number: 637 • 2014 ACR/ARHP Annual Meeting
Decreased Inflammatory Dendritic Cells in Lupus-Prone Estrogen Receptor Alpha Knockout (ERαKO) Mice Correlate with Increased Survival
Background/Purpose: SLE is a disease that disproportionately affects females. The etiology of the sex bias in this disease is unclear. We previously showed that a…Abstract Number: 2833 • 2014 ACR/ARHP Annual Meeting
SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study
Background/Purpose : SM101, which represents the human soluble non-glycosylated version of the Fcγ receptor IIB, binds to the Fc part of autoimmune complexes and inhibits…Abstract Number: 1643 • 2014 ACR/ARHP Annual Meeting
Role of Inflammasome Activation in Systemic Lupus Erthematosus: Are Innate Immune Cells Activated?
Background/Purpose Systemic lupus erythematosus (SLE) presents with a wide spectrum of clinical and immunologic abnormalities. On the other hand, exciting data is emerging about the…Abstract Number: 707 • 2014 ACR/ARHP Annual Meeting
Characteristics of Lupus Patients with Interstitial Lung Disease and Relationship with Jo-1 Antibody
Background/Purpose Pulmonary involvement is frequent in systemic lupus erythematosus (SLE) and can affect the pleura, pulmonary vasculature, and parenchyma. The prevalence of ILD is lower…Abstract Number: 485 • 2014 ACR/ARHP Annual Meeting
Incidence of Clinical and Serological Lupus-like Disease during Anti-Tnfα-Treatment – a Two-Year Prospective Study in an Interdisciplinary Patient Cohort
Background/Purpose: TNFα-Inhibitors are the most widely used biological agents in rheumatic conditions or other chronic inflammatory diseases. Over the last ten years, the occurrence of…Abstract Number: 2736 • 2014 ACR/ARHP Annual Meeting
Female Specific Increase in T Cell Glycosylation in Lupus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory disease characterized by altered T cell signaling. SLE is characterized by epigenetic mechanisms that cause hypomethylation…Abstract Number: 1629 • 2014 ACR/ARHP Annual Meeting
Added Value of the Determination of Anti-Ribosomal and Anti-Ku Antibodies for Diagnosis of Systemic Lupus Erythematosus
Background/Purpose Anti-dsDNA antibodies (aab) are known as important serological marker to aid in the diagnosis of systemic lupus erythematosus (SLE) and are part of the…Abstract Number: 698 • 2014 ACR/ARHP Annual Meeting
Grip Strength Identifies Increased Physical Disability in Women with Systemic Lupus Erythematosus
Background/Purpose: Muscle weakness is common and contributes to physical disability in women with systemic lupus erythematosus (SLE). Recently, the Foundation for the National Institutes of…Abstract Number: 77 • 2014 ACR/ARHP Annual Meeting
Epigenome Profiling Reveals Robust Hypomethylation of Interferon Signature Genes in Lupus Neutrophils
Background/Purpose: Lupus neutrophils play an important role in tissue damage (including glomerulonephritis and lupus skin involvement), as well as endothelial damage in lupus patients. Several…Abstract Number: 2741 • 2014 ACR/ARHP Annual Meeting
The Role of Fli1 in Lupus T Cell Function and Nephritis
Background/Purpose: The Ets factor Fli1 is implicated as a key modulator of lupus disease expression. Over-expressing Fli1 in healthy mice, results in the development of…Abstract Number: 1625 • 2014 ACR/ARHP Annual Meeting
Interferon Stimulates Transglutaminase Activity on Human Monocytes and Their Microparticles
Background/Purpose: Microparticles (MPs) are circulating membrane-bound vesicles derived from blood and endothelial cells via a highly regulated process. They are immunomodulatory and have been implicated…Abstract Number: 688 • 2014 ACR/ARHP Annual Meeting
Corticosteroids in Early Treatment Pathways in SLE
Background/Purpose: The treatment algorithm for patients with new onset systemic lupus erythematosus (SLE) is more variable than that for other rheumatic diseases (e.g. rheumatoid arthritis).…Abstract Number: L23 • 2014 ACR/ARHP Annual Meeting
Humoral Immune Response to Pneumococcal Polysaccharide Vaccine in SLE Patients on Immunosuppressive Therapy: Assessment of Serotypes without Protective Antibody Levels
Background/Purpose: Previous works assessing antibody response to pneumococcal polysaccharide vaccine (PPV) in systemic lupus erythematosus (SLE) relied exclusively on the quantitative increase in antibody titers…Abstract Number: 2676 • 2014 ACR/ARHP Annual Meeting
The E3 Ligase Casitas B Lineage Lymphoma b (Cbl-b) Modulates Peripheral Regulatory T Cell Function Via p27kip1 in Patients with Systemic Lupus Erythematosus
Background/Purpose: The interplay between effector and regulatory T cells (Tregs) is a key element among peripheral tolerance mechanisms in Systemic Lupus Erythematosus (SLE). Resistance to…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 31
- Next Page »